Non-thromboembolic risk in systemic lupus erythematosus associated with antiphospholipid syndrome

Objectives We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE). Methods In total, 224 patients with SLE were studied, of whom 105 were aPL-positi...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2014-08, Vol.23 (9), p.913-918
Main Authors: Deák, M, Bocskai, M, Burcsár, S, Dányi, O, Fekete, Z, Kovács, L
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anemia
Antibodies
Anticoagulants
Antiphospholipid Syndrome - complications
Disease
Endocarditis
Female
Humans
Laboratories
Lupus
Lupus Erythematosus, Systemic - complications
Male
Middle Aged
Retrospective Studies
Rheumatology
Risk Factors
Thrombocytopenia
Thromboembolism
Thromboembolism - etiology
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives We investigated the impact of secondary antiphospholipid syndrome (APS) and antiphospholipid antibody (aPL) positivity on the non-thromboembolic clinical manifestations of systemic lupus erythematosus (SLE). Methods In total, 224 patients with SLE were studied, of whom 105 were aPL-positive; 52 fulfilled the criteria for APS. SLE- and APS-related clinical and laboratory features were assesed: SLE patients with aPL or APS were compared with those without these features. Results Not only thromboembolic events, but also Coombs-positive haemolytic anaemia, thrombocytopenia and endocarditis occurred significantly more frequently in the aPL-positive than in the aPL-negative patients. In the APS + SLE subgroup, several non-thromboembolic symptoms occurred more often than in the absence of APS: pleuritis, interstitial lung disease, myocarditis, nephritis and organic brain syndrome. The mean number of major organ manifestations (1.2 vs. 0.5) and the overall number of organ manifestations (8.1 vs. 6.9) were higher in the APS + SLE patients than in those without APS (p 
ISSN:0961-2033
1477-0962
DOI:10.1177/0961203314531839